MAPT and Alzheimer disease: In addition, the model was proven accurate to predict Aβ-PET (AUC (95% CI) = 84 (81 to 87)) and tau-PET (AUC (95% CI) = 90 (87 to 93)) status as well as AD-related cognitive symptoms (AUC (95% CI) = 88 (84 to 92)) (Extended Data Fig. 7).